PARTICULATE (3'-CHLOROBIPHENYL-4-YL)(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YL)METHANONE AND METHODS OF ITS USE

1 . A particulate material, wherein the material is crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone.

2 . The particulate material of claim 1 , which has an mean particle size of less than about 5 μm.

3 . The particulate material of claim 2 , which has an mean particle size of less than about 4 μm.

4 . The particulate material of claim 3 , which has an mean particle size of less than about 3 μm.

5 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises a peak at about 4.7 degrees 2θ.

6 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 9.3 and 18.8 degrees 2θ.

7 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 19.7 and 22.4 degrees 2θ.

8 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 23.2 and 27.9 degrees 2θ.

9 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 29.6 and 32.2 degrees 2θ.

10 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 32.6 and 37.2 degrees 2θ.

11 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 41.6 and 42.3 degrees 2θ.

12 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that comprises peaks at about 9.3, 27.9 and 42.7 degrees 2θ.

13 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray powder diffraction pattern that is substantially the same as that shown in FIG. 1 .

14 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a Raman spectrum that is substantially the same as that shown in FIG. 2 .

15 . The particulate material of claim 1 , wherein the crystalline (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone has a melting point of about 117° C.

16 . A pharmaceutical formulation comprising the particulate material of claim 1 and a pharmaceutically acceptable excipient or diluent.

17 . The pharmaceutical formulation of claim 16 , which is a solid.

18 . The pharmaceutical formulation of claim 16 , which is a liquid suspension.

19 . A method of improving the cognitive performance of a human patient, which comprises administering to the patient an amount of the particulate material of claim 1 sufficient to improve the cognitive performance.

20 . A method of treating, managing or preventing a disease or disorder in a patient, which comprises administering to the patient a therapeutically or prophylactically effective amount of the particulate material of claim 1 , wherein the disease or disorder is age-associated memory impairment, Alzheimer's disease, Attention-Deficit/Hyperactivity Disorder, autism, Down syndrome, Fragile X syndrome, Huntington's disease, Parkinson's disease, or schizophrenia.